Chin Bin Eap

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


336 publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | ...
 
Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence - an update.
Fischer Fumeaux C.J., Morisod Harari M., Weisskopf E., Eap C.B., Epiney M., Vial Y., Csajka C., Bickle Graz M., Panchaud A., 2019/10. Expert opinion on drug safety, 18 (10) pp. 949-963. Peer-reviewed.
 
Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population.
Glatard A., Guidi M., Dobrinas M., Cornuz J., Csajka C., Eap C.B., 2019/07. European journal of clinical pharmacology, 75 (7) pp. 939-949. Peer-reviewed.
 
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al., 2019/05/29. British journal of clinical pharmacology. Peer-reviewed.
 
Lipid Disturbances in Adolescents Treated With Second-Generation Antipsychotics: Clinical Determinants of Plasma Lipid Worsening and New-Onset Hypercholesterolemia.
Delacrétaz A., Vandenberghe F., Glatard A., Dubath C., Levier A., Gholam-Rezaee M., Holzer L., Ambresin A.E., Conus P., Eap C.B., 2019/04/09. The Journal of clinical psychiatry, 80 (3). Peer-reviewed.
 
Genetic and clinic predictors of new onset diabetes mellitus after transplantation.
Saigi-Morgui N., Quteineh L., Bochud P.Y., Crettol S., Kutalik Z., Mueller N.J., Binet I., Van Delden C., Steiger J., Mohacsi P. et al., 2019/02. The pharmacogenomics journal, 19 (1) pp. 53-64. Peer-reviewed.
Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients.
Quteineh L., Wójtowicz A., Bochud P.Y., Crettol S., Vandenberghe F., Venetz J.P., Manuel O., Golshayan D., Lehmann R., Mueller N.J. et al., 2019/01. American journal of transplantation, 19 (1) pp. 238-246. Peer-reviewed.
 
WFSBP guidelines on how to grade treatment evidence for clinical guideline development.
Hasan A., Bandelow B., Yatham L.N., Berk M., Falkai P., Möller H.J., Kasper S., WFSBP Guideline Task Force Chairs, 2019/01. The world journal of biological psychiatry, 20 (1) pp. 2-16. Peer-reviewed.
Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances
Delacrétaz Aurélie, Vandenberghe Frederik, Glatard Anaïs, Levier Axel, Dubath Céline, Ansermot Nicolas, Crettol Séverine, Gholam-Rezaee Mehdi, Guessous Idris, Bochud Murielle et al., 2018/11/09. Frontiers in Psychiatry, 9.
 
Les antidépresseurs sont-ils efficaces ?
Hengartner Michael P. , Eap Chin Bin , 2018/10/19. Psychoscope 6 p. 34.
The effect of a single dose of escitalopram on sensorimotor networks.
Weisstanner C., Kägi G., Krammer W., Eap C.B., Wiest R., Missimer J.H., Weder B.J., 2018/06. Brain and behavior, 8 (6) pp. e00975. Peer-reviewed.
 
Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study.
Ponte B., Pruijm M., Ackermann D., Ehret G., Ansermot N., Staessen J.A., Vogt B., Pechère-Bertschi A., Burnier M., Martin P.Y. et al., 2018/05. Mayo Clinic proceedings, 93 (5) pp. 586-596. Peer-reviewed.
Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain.
Vandenberghe F., Najar-Giroud A., Holzer L., Conus P., Eap C.B., Ambresin A.E., 2018/05. Journal of child and adolescent psychopharmacology, 28 (4) pp. 258-265. Peer-reviewed.
Psychotropic Drug Prescription in Adolescents: A Retrospective Study in a Swiss Psychiatric University Hospital.
Ansermot N., Jordanov V., Smogur M., Holzer L., Eap C.B., 2018/04. Journal of child and adolescent psychopharmacology, 28 (3) pp. 192-204. Peer-reviewed.
N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis.
Conus P., Seidman L.J., Fournier M., Xin L., Cleusix M., Baumann P.S., Ferrari C., Cousins A., Alameda L., Gholam-Rezaee M. et al., 2018/02/15. Schizophrenia bulletin, 44 (2) pp. 317-327. Peer-reviewed.
Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia.
Delacrétaz A., Vandenberghe F., Gholam-Rezaee M., Saigi Morgui N., Glatard A., Thonney J., Solida-Tozzi A., Kolly S., Gallo S.F., Baumann P. et al., 2018. Journal of clinical lipidology, 12 (1) pp. 219-229. Peer-reviewed.
Gender-specific alteration of energy balance and circadian locomotor activity in the Crtc1 knockout mouse model of depression.
Rossetti C., Sciarra D., Petit J.M., Eap C.B., Halfon O., Magistretti P.J., Boutrel B., Cardinaux J.R., 2017/12/08. Translational psychiatry, 7 (12) p. 1269. Peer-reviewed.
Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs.
Delacrétaz A., Lagares Santos P., Saigi Morgui N., Vandenberghe F., Glatard A., Gholam-Rezaee M., von Gunten A., Conus P., Eap C.B., 2017/12. Pharmacogenetics and genomics, 27 (12) pp. 464-472. Peer-reviewed.
Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring
Forni Ogna Valentina, Bassi Isabelle, Menetrey Isabelle, Muller Olivier, Tousset Eric, Fontana Pierre, Eeckhout Eric, Eap Chin B., Vrijens Bernard, Burnier Michel et al., 2017/10/25. Frontiers in Pharmacology, 8 pp. NA. Peer-reviewed.
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.
Glatard A., Dobrinas M., Gholamrezaee M., Lubomirov R., Cornuz J., Csajka C., Eap C.B., 2017/10. Experimental and clinical psychopharmacology, 25 (5) pp. 353-362. Peer-reviewed.
Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs.
Delacrétaz A., Zdralovic A., Vandenberghe F., Saigi-Morgui N., Glatard A., Quteineh L., Gholam-Rezaee M., Raffoul W., Applegate L.A., Jafari P. et al., 2017/09/10. Gene, 628 pp. 8-15. Peer-reviewed.
Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study.
Sikhayeva N., Iskakova A., Saigi-Morgui N., Zholdybaeva E., Eap C.B., Ramanculov E., 2017/07/24. BMC medical genetics, 18 (1) p. 76. Peer-reviewed.
 
Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry.
Weisskopf E., Panchaud A., Nguyen K.A., Grosjean D., Hascoët J.M., Csajka C., Eap C.B., Ansermot N., collaborators of the SSRI-Breast Milk study, 2017/07/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1057 pp. 101-109. Peer-reviewed.
 
N-acetyl-cysteine in a double-blind randomized placebo-controlled trial: Towards biomarker guided treatment in early psychosis
Conus P., Fournier M., Xin L., Baumann P., Ferrari C., Cousins A., Alameda L., Golay P., Jenni R., Kashavan M.S. et al., 2017/04. pp. S806 dans European Psychiatry, Elsevier BV.
 
SA19. N-Acetyl-Cysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
Do Kim, Seidman Larry J., Fournier Margot, Xin Lijing, Cleusix Martine, Baumann Philipp S., Ferrari Carina, Cousins Ann, Alameda Luis, Gholam-Rezaee Mehdi et al., 2017/03/01. pp. S119-S120 dans Schizophrenia Bulletin, Oxford University Press (OUP).
 
Étude rétrospective sur le suivi électrocardiographique (ECG) des patients hospitalisés en psychiatrie adulte
Ansermot N., Bochatay M., Schläpfer J., Gholamrezaee M., Gonthier A., Conus P., Eap C., 2017/03., 20e journées franco-suisses de pharmacie hospitalière pp. e15-e16 dans Le Pharmacien Hospitalier et Clinicien, Elsevier BV.
 
Association of genetic risk scores with body mass index in Swiss psychiatric cohorts
Saigi-Morgui Nuria, Vandenberghe Frederik, Delacrétaz Aurélie, Quteineh Lina, Gholamrezaee Mehdi, Kutalik Zoltan, Aubry Jean Michel, von Gunten Armin, Conus Philippe, Eap Chin B., 2017., 23rd Annual world congress of Psychiatric Genetics (WCPG), Toronto, Canada pp. S248 dans European Neuropsychopharmacology, Elsevier BV.
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation.
Quteineh L., Bochud P.Y., Golshayan D., Crettol S., Venetz J.P., Manuel O., Kutalik Z., Treyer A., Lehmann R., Mueller N.J. et al., 2017/01. The pharmacogenomics journal, 17 (1) pp. 69-75. Peer-reviewed.
 
Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior.
Cornelis M.C., Kacprowski T., Menni C., Gustafsson S., Pivin E., Adamski J., Artati A., Eap C.B., Ehret G., Friedrich N. et al., 2016/12/15. Human molecular genetics, 25 (24) pp. 5472-5482. Peer-reviewed.
 
Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study.
Forni Ogna V., Menetrey I., Muller O., Tousset E., Guihard L., Fontana P., Eeckhout E., Eap C.B., Vrijens B., Burnier M. et al., 2016/12. British Journal of Clinical Pharmacology, 82 (6) pp. 1486-1497. Peer-reviewed.
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.
Csajka C., Crettol S., Guidi M., Eap C.B., 2016/12. Clinical pharmacokinetics, 55 (12) pp. 1521-1533. Peer-reviewed.
Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers.
Vandenberghe F., Saigí-Morgui N., Delacrétaz A., Quteineh L., Crettol S., Ansermot N., Gholam-Rezaee M., von Gunten A., Conus P., Eap C.B., 2016/12. Pharmacogenetics and genomics, 26 (12) pp. 547-557. Peer-reviewed.
 
Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry.
Weisskopf E., Panchaud A., Nguyen K.A., Grosjean D., Hascoët J.M., Csajka C., Eap C.B., Ansermot N., collaborators of the SSRI-Breast Milk study, 2016/11/30. Journal of pharmaceutical and biomedical analysis, 131 pp. 233-245. Peer-reviewed.
Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs.
Eap C.B., 2016/09. Dialogues in clinical neuroscience, 18 (3) pp. 313-322. Peer-reviewed.
Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression.
Quteineh L., Preisig M., Rivera M., Milaneschi Y., Castelao E., Gholam-Rezaee M., Vandenberghe F., Saigi-Morgui N., Delacrétaz A., Cardinaux J.R. et al., 2016/07/01. Journal of affective disorders, 198 pp. 43-49. Peer-reviewed.
 
Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts.
Marie-Claire C., Crettol S., Cagnard N., Bloch V., Mouly S., Laplanche J.L., Bellivier F., Lepine J.P., Eap C., Vorspan F., 2016/02. Epigenomics, 8 (2) pp. 181-195. Peer-reviewed.
Association of genetic risk scores with body mass index in Swiss psychiatric cohorts.
Saigi-Morgui N., Vandenberghe F., Delacrétaz A., Quteineh L., Gholamrezaee M., Aubry J.M., von Gunten A., Kutalik Z., Conus P., Eap C.B., 2016. Pharmacogenetics and Genomics, 26 (5) pp. 208-217. Peer-reviewed.
 
Bon usage des antidépresseurs ISRS durant la grossesse--le défi de l'évaluation de la balance bénéfice-risque [SSRI antidepressant use during pregnancy and the assessment of the risk-benefit ratio].
Weisskopf E., Fumeaux C.J., Bickle Graz M., Harari M.M., Epiney M., Tolsa C.B., Rouiller S., Tolsa J.F., Eap C.B., Vial Y. et al., 2016. Revue Médicale Suisse, 12 (510) pp. 561-566. Peer-reviewed.
Eine unerwünschte Wirkung von Methadon und Moxifloxacin
Liakoni E., Huber X., Stegert M., Crettol S., Eap CB., Liechti ME., 2016. Schweizerisches Medizin-Forum, 16 pp. 176-177. Peer-reviewed.
Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone.
Paulzen M., Eap C.B., Gründer G., Kuzin M., 2016. Journal of Clinical Psychopharmacology, 36 (1) pp. 90-92. Peer-reviewed.
 
Psychiatrie [New developments in psychiatry].
Conus P., Herrera F., Berney S., Gailland B., Beretta V., Vandenberghe F., Eap C.B., 2016. Revue Médicale Suisse, 12 (500) pp. 86-89.
Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population.
Petrovic D., Estoppey Younes S., Pruijm M., Ponte B., Ackermann D., Ehret G., Ansermot N., Mohaupt M., Paccaud F., Vogt B. et al., 2016. Nutrition & metabolism, 13 p. 81. Peer-reviewed.
Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations.
Saigi-Morgui N., Quteineh L., Bochud P.Y., Crettol S., Kutalik Z., Wojtowicz A., Bibert S., Beckmann S., Mueller N.J., Binet I. et al., 2016. PloS one, 11 (10) pp. e0164443. Peer-reviewed.
Wolff-Parkinson-White syndrome in an adolescent with depression
Chen Fei, Richard Sandra, D'Andrea Géraldine, Grandjean Christophe, Eap Chin B., 2016. Swiss Archives of Neurology Psychiatry and Psychotherapy, 167 (3) pp. 94-96. Peer-reviewed.
 
1C.06: Ambulatory pulse pressure is negatively associated with excretions of urinary caffeine and its metabolites
Guessous I., Pruijm M., Ponte B., Ehret G., Ansermot N., Vuistiner P., Staessen J.A., Gu Y.M., Paccaud F., Mohaupt M.G. et al., 2015/06., ESH 2015: 25th European meeting on hypertension and cardiovascular protection, 12-15 June 2015, Milan (Italy) pp. e10-e11 dans J Hypertension. Peer-reviewed.
 
Adolescent psychotropic drug use in a Swiss psychiatric university hospital: retrospective studies in 2008 and 2014
Jordanov V., Smogur M., Holzer L., Eap C., Ansermot N., 2015. dans GSASA-Kongress 2015.
Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments.
Saigi-Morgui N., Vandenberghe F., Delacrétaz A., Quteineh L., Choong E., Gholamrezaee M., Magistretti P., Aubry J.M., von Gunten A., Preisig M. et al., 2015. Journal of Clinical Psychopharmacology, 35 (5) pp. 544-552. Peer-reviewed.
 
Associations of ambulatory blood pressure with urinary caffeine and caffeine metabolite excretions.
Guessous I., Pruijm M., Ponte B., Ackermann D., Ehret G., Ansermot N., Vuistiner P., Staessen J., Gu Y., Paccaud F. et al., 2015. Hypertension, 65 (3) pp. 691-696. Peer-reviewed.
 
Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.
Liu Y., Jann M., Vandenberg C., Eap C.B., Shamsi S.A., 2015. Journal of Chromatography. A, 1420 pp. 119-128. Peer-reviewed.
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
Vandenberghe F., Guidi M., Choong E., von Gunten A., Conus P., Csajka C., Eap C.B., 2015. Clinical Pharmacokinetics, 54 (12) pp. 1259-1272. Peer-reviewed.
Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments.
Quteineh L., Vandenberghe F., Saigi Morgui N., Delacrétaz A., Choong E., Gholam-Rezaee M., Magistretti P., Bondolfi G., Von Gunten A., Preisig M. et al., 2015. Pharmacogenetics and Genomics, 25 (5) pp. 246-258. Peer-reviewed.
Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.
Vandenberghe F., Gholam-Rezaee M., Saigí-Morgui N., Delacrétaz A., Choong E., Solida-Tozzi A., Kolly S., Thonney J., Gallo S.F., Hedjal A. et al., 2015. Journal of Clinical Psychiatry, 76 (11) pp. e1417-e1423. Peer-reviewed.
Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression.
Delacrétaz A., Preisig M., Vandenberghe F., Saigi Morgui N., Quteineh L., Choong E., Gholam-Rezaee M., Kutalik Z., Magistretti P., Aubry J.M. et al., 2015. Plos One, 10 (10) pp. e0139155. Peer-reviewed.
 
Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence.
Weisskopf E., Fischer C.J., Bickle Graz M., Morisod Harari M., Tolsa J.F., Claris O., Vial Y., Eap C.B., Csajka C., Panchaud A., 2015. Expert Opinion On Drug Safety, 14 (3) pp. 413-427. Peer-reviewed.
 
Severe manic episode associated with tramadol in a patient with recurrent depressive disorder.
Ansermot N., Chocron O., Herrera F., Eap C.B., 2015. Journal of Clinical Psychopharmacology, 35 (2) pp. 203-204. Peer-reviewed.
 
The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens.
Sakae D.Y., Marti F., Lecca S., Vorspan F., Martín-García E., Morel L.J., Henrion A., Gutiérrez-Cuesta J., Besnard A., Heck N. et al., 2015. Molecular Psychiatry, 20 (11) pp. 1448-1459. Peer-reviewed.
 
Blood pressure in relation to coffee and caffeine consumption.
Guessous I., Eap C.B., Bochud M., 2014. Current Hypertension Reports, 16 (9) p. 468. Peer-reviewed.
Can Valproic Acid be an Inducer of Clozapine Metabolism?
Diaz F.J., Eap C.B., Ansermot N., Crettol S., Spina E., de Leon J., 2014. Pharmacopsychiatry, 47 (3) pp. 89-96. Peer-reviewed.
 
CRTC3 Polymorphisms are not associated with obesity in swiss psychiatric populations
Quteineh L, Vandenberghe F, Rezaee MG, Choong E, Morgui NS, Delacretaz A, Preisig M, Von Gunten A, Conus P, Eap C., 2014. dans European Psychiatry. Peer-reviewed.
 
Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique [Pharmacokinetic Alterations in Pregnancy and Use of Therapeutic Drug Monitoring].
Panchaud A., Weisskopf E., Winterfeld U., Baud D., Guidi M., Eap C.B., Csajka C., Widmer N., 2014. Therapie, 69 (3) pp. 223-234. Peer-reviewed.
 
Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.
Crettol S., de Leon J., Hiemke C., Eap C.B., 2014. Clinical Pharmacology and Therapeutics, 95 (3) pp. 254-257. Peer-reviewed.
 
Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a nonfatal overdose during a suicide attempt.
Paulzen M., Henkel K., Tauber S., Reich A., Eap C.B., Gründer G., 2014. Journal of Clinical Psychopharmacology, 34 (3) pp. 398-399. Peer-reviewed.
 
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.
Noetzli M., Guidi M., Ebbing K., Eyer S., Wilhelm L., Michon A., Thomazic V., Stancu I., Alnawaqil A.M., Bula C. et al., 2014. British Journal of Clinical Pharmacology, 78 (1) pp. 135-144. Peer-reviewed.
 
Predictive values of affpetite and early weight increase for long-term weight variation during psychotropic treatment
Vandenberghe F, Rezaee MG, Choong E, Morgui NS, Delacretaz A, Preisig M, Von Gunten A, Conus P, Eap C., 2014. dans European Psychiatry. Peer-reviewed.
 
Prescription de médicaments psychotropes chez des adolescents hospitalisés en milieu psychiatrique
Ansermot N, Smogur M, Holzer L, Eap Chin B, 2014. dans 2ème congrès suisse des pharmaciens.
 
Quantification of typical antipsychotics in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring.
Gradinaru J., Vullioud A., Eap C.B., Ansermot N., 2014. Journal of Pharmaceutical and Biomedical Analysis, 88 pp. 36-44. Peer-reviewed.
 
Serotonin toxicity after addition of mirtazapine to escitalopram.
Ansermot N., Hodel P.F., Eap C.B., 2014. Journal of Clinical Psychopharmacology, 34 (4) pp. 540-541. Peer-reviewed.
 
Antidépresseurs, grossesse et allaitement : une étude multicentrique
Weisskopf E., Lepigeon K., Fischer C., Morisod M., Bickle M., Eap C.B., Tolsa J-F., Vial Y., Csajka C., Panchaud A., 2013. Forum Gynécologie Suisse, 13 (2) pp. 4-6.
 
Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry.
Lüthi G., Blangy V., Eap C.B., Ansermot N., 2013. Journal of Pharmaceutical and Biomedical Analysis, 77 pp. 1-8. Peer-reviewed.
 
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M., Crettol S., Oneda B., Lahyani R., Rotger M., Choong E., Lubomirov R., Csajka C., Eap C.B., 2013. Pharmacogenetics and Genomics, 23 (2) pp. 84-93. Peer-reviewed.
 
Cytochrom-P450-Genotypisierung: ein Instrument zur Personalisierung der medikamentösenBehandlung in der Psychiatrie
Crettol Séverine, Eap Chin Bin, 2013. Pipette : Swiss Laboratory Medicine 6 pp. 10-11.
 
Cytochromes P450: génotypage et /ou phénotypage pour l'individualisation du traitement médicamenteux
Crettol Séverine, Eap Chin B., 2013. Pipette 1 pp. 10-11.
 
Etude multicentrique: antidépresseurs, grossesse et allaitement.
Weisskopf E., Lepigeon K., Fischer C., Morisod M., Bickle M., Eap C.B., Tolsa J.F., Vial Y., Csajka C., Panchaud A., 2013. Forum Gynécologie Suisse, 13 (2) pp. 4-6.
 
Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring.
Ansermot N., Brawand-Amey M., Kottelat A., Eap C.B., 2013. Journal of Chromatography. A, 1292 pp. 160-172. Peer-reviewed.
 
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
Fayet-Mello A., Buclin T., Guignard N., Cruchon S., Cavassini M., Grawe C., Gremlich E., Popp K.A., Schmid F., Eap C.B. et al., 2013. Antiviral Therapy, 18 (2) pp. 171-182. Peer-reviewed.
Influence of CRTC1 Polymorphisms on Body Mass Index and Fat Mass in Psychiatric Patients and the General Adult Population.
Choong E., Quteineh L., Cardinaux J.R., Gholam-Rezaee M., Vandenberghe F., Dobrinas M., Bondolfi G., Etter M., Holzer L., Magistretti P. et al., 2013. JAMA Psychiatry, 70 (10) pp. 1011-1019. Peer-reviewed.
 
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Noetzli M., Eap C.B., 2013. Clinical Pharmacokinetics, 52 (4) pp. 225-241. Peer-reviewed.
 
Pharmacogenetic Study on Risperidone Long-Acting Injection: Influence of Cytochrome P450 2D6 and Pregnane X Receptor on Risperidone Exposure and Drug-Induced Side-Effects.
Choong E., Polari A., Kamdem R.H., Gervasoni N., Spisla C., Sirot E.J., Bickel G.G., Bondolfi G., Conus P., Eap C.B., 2013. Journal of Clinical Psychopharmacology, 33 (3) pp. 289-298. Peer-reviewed.
 
Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers.
Dobrinas M., Cornuz J., Eap C.B., 2013. Pharmacogenetics and Genomics, 23 (5) pp. 286-292. Peer-reviewed.
 
Population pharmacokinetic study of memantine: effects of clinical and genetic factors.
Noetzli M., Guidi M., Ebbing K., Eyer S., Wilhelm L., Michon A., Thomazic V., Alnawaqil A.M., Maurer S., Zumbach S. et al., 2013. Clinical Pharmacokinetics, 52 (3) pp. 211-223. Peer-reviewed.
 
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., Eap C.B., Decosterd L.A., Csajka C., 2013. British Journal of Clinical Pharmacology, 75 (4) pp. 1007-1018. Peer-reviewed.
 
Psychiatrie [Psychiatry].
Conus P., Despland J.N., Herrera F., Chanachev A., Eap C.B., Mall J.F., Ebbing K., von Gunten A., 2013. Revue Médicale Suisse, 9 (368) pp. 76-79. Peer-reviewed.
 
Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations.
Noetzli M., Guidi M., Ebbing K., Eyer S., Zumbach S., Giannakopoulos P., von Gunten A., Csajka C., Eap C.B., 2013. Therapeutic Drug Monitoring, 35 (2) pp. 270-275. Peer-reviewed.
 
Use of High Doses of Quetiapine in Bipolar Disorder Episodes are not Linked to High Activity of Cytochrome P4503A4 and/or Cytochrome P4502D6.
Khazaal Y., Preisig M., Chatton A., Kaufmann N., Bilancioni R., Eap C.B., 2013. Psychiatric Quarterly, 84 (3) pp. 329-335. Peer-reviewed.
 
Adherence to antidepressant treatment: what the doctor thinks and what the patient says.
Loayza N., Crettol S., Riquier F., Eap C.B., 2012. Pharmacopsychiatry, 45 (5) pp. 204-207. Peer-reviewed.
 
Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension.
Guessous I., Dobrinas M., Kutalik Z., Pruijm M., Ehret G., Maillard M., Bergmann S., Beckmann J.S., Cusi D., Rizzi F. et al., 2012. Human Molecular Genetics, 21 (14) pp. 3283-3292. Peer-reviewed.
 
Clinical effectiveness, pharmacokinetics and pharmacogenetics of mirtazapine in depression
Jaquenoud Sirot E., Harenberg S., Vandel P., Mendonça Lima C.A., Perrenoud P., Kemmerling K., Zullino D.F., Hilleret H., Crettol S., Jonzier-Perey M. et al., 2012. pp. 45 - A10 dans Psychotropic Drugs: Risks and Risk Management : Xth Congress of the Interdisciplinary TDM Task Force of the AGNP together with the Swiss Society for Pharmacovigilance in Psychiatry (SGAMSP) and the Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP), Pharmacopsychiatry. Peer-reviewed.
 
Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial
Dahmane E., Zaman K., Galmiche Rindisbacher M., Berthod G., Perey L., Bodmer A., Leyvraz S., Eap C., Decosterd L., Buclin T. et al., 2012. pp. 108S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
 
Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking.
Dobrinas M., Cornuz J., Pedrido L., Eap C.B., 2012. Pharmacogenetics and Genomics, 22 (2) pp. 143-151. Peer-reviewed.
 
Matched case-control study: therapeutic drug monitoring in pharmacovigilance
Jaquenoud Sirot E., Stephan P.L., Eap C.B., van der Velden J.W., Baumann P., 2012. pp. 45 - A11 dans Psychotropic Drugs: Risks and Risk Management : Xth Congress of the Interdisciplinary TDM Task Force of the AGNP together with the Swiss Society for Pharmacovigilance in Psychiatry (SGAMSP) and the Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP), Pharmacopsychiatry. Peer-reviewed.
 
Monographs on drugs which are frequently analyzed in therapeutic drug monitoring/Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden
Eap Bin, 2012/01/01..
 
Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression.
Jaquenoud Sirot E., Harenberg S., Vandel P., Lima C.A., Perrenoud P., Kemmerling K., Zullino D.F., Hilleret H., Crettol S., Jonzier-Perey M. et al., 2012. Journal of Clinical Psychopharmacology, 32 (5) pp. 622-629. Peer-reviewed.
 
Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population.
Choong E., Bondolfi G., Etter M., Jermann F., Aubry J.M., Bartolomei J., Gholam-Rezaee M., Eap C.B., 2012. Journal of Psychiatric Research, 46 (4) pp. 540-548. Peer-reviewed.
 
Simultaneous determination of antidementia drugs in human plasma: Procedure transfer from HPLC-MS to UPLC-MS/MS.
Noetzli M., Ansermot N., Dobrinas M., Eap C.B., 2012. Journal of Pharmaceutical and Biomedical Analysis, 64-65 pp. 16-25. Peer-reviewed.
 
Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring.
Ansermot N., Brawand-Amey M., Eap C.B., 2012. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 885-886 pp. 117-130. Peer-reviewed.
 
La pharmacogénétique/pharmacogénomique en psychiatrie, perspectives théoriques et perspectives pour l'avenir
Chanachev Aleksandar, Conus Philippe, Eap Chin Bin, 2011/11. L'information psychiatrique, 87 (9) pp. 697-703.
 
Syndrome métabolique et antipsychotiques atypiques : recommandations et prise en charge clinique
Solida Alessandra, Choong Eva, Lechaire Catherine, Eap Chin Bin, Conus Philippe, 2011/11. L'information psychiatrique, 87 (9) pp. 715-724.
Addition of aripiprazole to the clozapine may be useful in reducing anxiety in treatment-resistant schizophrenia.
Chanachev A., Ansermot N., Crettol Wavre S., Nowotka U., Stamatopoulou M.E., Conus P., Eap C.B., 2011. Case Reports In Psychiatry, 2011 p. 846489. Peer-reviewed.
 
Cytochrome P450 1A2 activity and inducibility: impact of smoking, smoking cessation and genetic polymorphisms
Dobrinas M., Cornuz J., Oneda B., Kohler S.M., Puhl M., Eap C.B., 2011. p. 473 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Therapeutic Drug Monitoring. Peer-reviewed.
 
Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study.
Nikisch G., Baumann P., Oneda B., Kiessling B., Weisser H., Mathé A.A., Yoshitake T., Kehr J., Wiedemann G., Eap C.B., 2011. Journal of Psychopharmacology, 25 (7) pp. 896-907. Peer-reviewed.
 
Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility.
Dobrinas M., Cornuz J., Oneda B., Kohler Serra M., Puhl M., Eap C.B., 2011. Clinical Pharmacology and Therapeutics, 90 (1) pp. 117-125. Peer-reviewed.
 
Monographs on drugs which are frequently analyzed in therapeutic drug monitoring/Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden
Rentsch Katharina, Buhl Daniela, Eap Chin Bin, Fathi Marc, Thormann Wolfgang, Werner Dominique, 2011/01. LaboratoriumsMedizin, 35 (2) pp. 81-91. Peer-reviewed.
 
Psychiatrie [Psychiatry].
Guex P., Conus P., Pomini V., Kramer U., Bonsack C., Eap C., 2011. Revue Médicale Suisse, 7 (278) pp. 150-153. Peer-reviewed.
 
Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring.
Choong E., Rudaz S., Kottelat A., Haldemann S., Guillarme D., Veuthey J.L., Eap C.B., 2011. Journal of Chromatography. B, 879 (19) pp. 1544-1550. Peer-reviewed.
 
Quantification of nicotine, cotinine, trans-3'-hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC-tandem mass-spectrometry procedure for a clinical study on smoking cessation.
Dobrinas M., Choong E., Noetzli M., Cornuz J., Ansermot N., Eap C.B., 2011. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 879 (30) pp. 3574-3582. Peer-reviewed.
 
Simultaneous determination of antidementia drugs by HPLC-MS: validation data of the method and plasma level determinations in 300 patients
Noetzli M., Choong E., Ansermot N., Eap C.B., 2011. p. 501 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Therapeutic Drug Monitoring. Peer-reviewed.
 
Simultaneous determination of antidementia drugs in human plasma for therapeutic drug monitoring.
Noetzli M., Choong E., Ansermot N., Eap C.B., 2011. Therapeutic Drug Monitoring, 33 (2) pp. 227-238. Peer-reviewed.
 
Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz.
Pelet A., Favrat B., Cavassini M., Eap C.B., Besson J., Monnat M., 2011. American Journal of Drug and Alcohol Abuse, 37 (4) pp. 264-268. Peer-reviewed.
 
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
Oneda B., Crettol S., Bochud M., Besson J., Croquette-Krokar M., Hämmig R., Monnat M., Preisig M., Eap C.B., 2011. Pharmacogenomics Journal, 11 (4) pp. 258-266. Peer-reviewed.
 
Does Methadone Prolong QTc Intervals by Depleting Testosterone Levels?—Reply
Ansermot Nicolas, Albayrak Oezguer, Schlaepfer Juerg, Wavre Crettol Séverine, Croquette-Krokar Marina, Bourquin Michel, Deglon J.J., Faouzi M., Rey F., Scherbaum N. et al., 2010/08/09. Archives of Internal Medicine, 170 (15) p. 1407. Peer-reviewed.
 
Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval.
Ansermot N., Albayrak O., Schläpfer J., Crettol S., Croquette-Krokar M., Bourquin M., Déglon J.J., Faouzi M., Scherbaum N., Eap C.B., 2010/03/22. Archives of internal medicine, 170 (6) pp. 529-536. Peer-reviewed.
 
Evidence-based medicine for pharmacogenetics
Rossier Michel F., Rebsamen Michaela, Crettol Severine, Eap Chin B., Rentsch Katharina, 2010. Pipette : Swiss Loboratory Medicine 4 pp. 13-15.
 
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer C.F., Daali Y., Wagner M., Hopfgartner G., Eap C.B., Rebsamen M.C., Rossier M.F., Hochstrasser D., Dayer P., Desmeules J.A., 2010. British Journal of Pharmacology, 160 (4) pp. 919-930. Peer-reviewed.
 
Lack of Association Between Genetic Polymorphisms of ARRB2 and Alcohol Dependence in a Caucasian Population.
Oneda B., Preisig M., Dobrinas M., Eap C.B., 2010. Alcohol and Alcoholism, 45 (6) pp. 590-591. Peer-reviewed.
 
Monographs on drugs which are frequently analyzed in therapeutic drug monitoring = Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden
Rentsch K., Buhl D., Eap C.B., Fathi M., Jöchle W., Magnin J.L., Thormann W., Werner D., 2010. Laboratoriums-Medizin = Journal of Laboratory Medicine, 34 (3) pp. 129-139. Peer-reviewed.
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.
Zaman K., Dahmane E., Perey L., Buclin T., Berthod G., Bodmer A., Galmiche M., Leyvraz S., Eap C., Csajka C. et al., 2010. dans 33rd Annual San Antonio Breast Cancer Symposium.
 
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer C.F., Daali Y., Wagner M., Hopfgartner G., Eap C.B., Rebsamen M.C., Rossier M.F., Hochstrasser D., Dayer P., Desmeules J.A., 2010. British Journal of Pharmacology, 160 (4) pp. 907-918. Peer-reviewed.
 
The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution.
Choong E., Dobrinas M., Carrupt P.A., Eap C.B., 2010. Expert Opinion On Drug Metabolism and Toxicology, 6 (8) pp. 953-965. Peer-reviewed.
 
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B., Crettol S., Jaquenoud Sirot E., Bochud M., Ansermot N., Eap C.B., 2009/11. Pharmacogenetics and genomics, 19 (11) pp. 877-883. Peer-reviewed.
Tamoxifen metabolism and the impact of Tamoxifen dose on the level of the active metabolites in endocrine sensitive breast cancer patients
Dahmane Elyes, Csajka Chantal, Decosterd Laurent, Mercier Thomas, Zanolari Boris, Eap Chin, Buclin Thierry, Galmiche Marie, Zaman Khalil, 2009/09. dans ''Frontiers in drug discovery and development'' : 24ème séminaire, 3ème cycle, en sciences pharmaceutiques.
 
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E., Knezevic B., Morena G.P., Harenberg S., Oneda B., Crettol S., Ansermot N., Baumann P., Eap C.B., 2009. Journal of clinical psychopharmacology, 29 (4) pp. 319-26. Peer-reviewed.
 
Aspects génétiques de la consommation de tabac et prise en charge clinique [Genetic aspects of smoking and impact on clinical care]
Dobrinas M., Cornuz J., Kohler Serra M., Puhl M., Eap C.B., 2009. Revue médicale suisse, 5 (210) pp. 1463-7. Peer-reviewed.
Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study.
Hallinan R., Crettol S., Agho K., Attia J., Besson J., Croquette-Krokar M., Hämmig R., Déglon J.J., Byrne A., Ray J. et al., 2009. European Journal of Clinical Pharmacology, 65 (11) pp. 1113-1120.
 
CYP3A5 and ABCB1 genes and hypertension.
Bochud M., Bovet P., Burnier M., Eap C.B., 2009. Pharmacogenomics, 10 (3) pp. 477-487. Peer-reviewed.
 
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J., Fayet A., Arab-Alameddine M., Rotger M., Lubomirov R., Cavassini M., Furrer H., Günthard H.F., Colombo S., Csajka C. et al., 2009. Pharmacogenetics and Genomics, 19 (4) pp. 300-309. Peer-reviewed.
Monographs on drugs which are frequently analyzed in therapeutic drug monitoring
Rentsch K., Eap C.B., Fathi M., Grignaschi N., Magnin J.L., Thormann W., Todesco L., Werner D., 2009. Journal of Laboratory and Clinical Medicine, 33 (2) pp. 99-120.
 
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M., Di Iulio J., Buclin T., Rotger M., Lubomirov R., Cavassini M., Fayet A., Décosterd L.A., Eap C.B., Biollaz J. et al., 2009. Clinical Pharmacology and Therapeutics, 85 (5) pp. 485-494. Peer-reviewed.
 
Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS.
Choong E., Rudaz S., Kottelat A., Guillarme D., Veuthey J.L., Eap C.B., 2009. Journal of Pharmaceutical and Biomedical Analysis, 50 (5) pp. 1000-1008. Peer-reviewed.
 
Un regard sur la schizophrénie
Bertholet Léa, Do Kim Q., Schenk Françoise, Ansermot Nicolas, Eap Chin B., 2009. Actualités psychologiques 22 pp. 77-106.
 
Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples.
Ansermot N., Rudaz S., Brawand-Amey M., Fleury-Souverain S., Veuthey J.L., Eap C.B., 2009. Journal of Chromatography. B, 877 (23) pp. 2301-2307. Peer-reviewed.
 
Suivi du syndrome métabolique induit par les antipsychotiques atypiques: recommandations et perspectives pharmacogénétiques [Follow-up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives]
Choong E., Solida A., Lechaire C., Conus P., Eap C.B., 2008/09/17. Revue medicale suisse, 4 (171) pp. 1994-1996,1998-1999. Peer-reviewed.
 
CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M., Eap C.B., Oneda B., Gervasoni N., Aubry J.M., Bondolfi G., Bertschy G., 2008/08. Therapeutic drug monitoring, 30 (4) pp. 474-482. Peer-reviewed.
 
Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.
Fayet A., Béguin A., de Tejada B.M., Colombo S., Cavassini M., Gerber S., Eap C.B., Telenti A., Buclin T., Biollaz J. et al., 2008/08. Therapeutic drug monitoring, 30 (4) pp. 511-522. Peer-reviewed.
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008/07/16. Revue medicale suisse, 4 (165) pp. 1644-1648. Peer-reviewed.
 
ABCB1 and cytochromes P450 genotypes and phenotypes: influence on clozapine plasma concentrations
Jaquenoud Sirot Eveline, Knezevic B., Perla Morena Gina, Baumann Pierre, Eap Chin Bin, 2008. pp. e465 dans , Canadian Journal of Clinical Pharmacology = Journal canadien de pharmacologie clinique. Peer-reviewed.
Association of ABCB1 genetic variants with renal function in Africans and in Caucasians.
Bochud M., Eap C.B., Maillard M., Johnson T., Vollenweider P., Bovet P., Elston R.C., Bergmann S., Beckmann J.S., Waterworth D.M. et al., 2008. BMC Medical Genomics, 1 (21) pp. 1-11. Peer-reviewed.
 
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.
Crettol S., Besson J., Croquette-Krokar M., Hämmig R., Gothuey I., Monnat M., Déglon J.J., Preisig M., Eap C.B., 2008. Progress in Neuro-psychopharmacology and Biological Psychiatry, 32 (7) pp. 1722-1727. Peer-reviewed.
 
Brain dopamine response in human opioid addiction
Daglish Mark R.C., Williams Tim M., Wilson Sue J., Taylor Lindsay G., Eap Chin, Augsburger Marc, Giroud Christian, Brooks David J., Myles Judy S., Grasby Paul et al., 2008. British Journal of Psychiatry, 193 (1) pp. 65-72. Peer-reviewed.
 
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study.
Nikisch G., Eap C.B., Baumann P., 2008. Pharmacological research, 58 (5-6) pp. 344-347. Peer-reviewed.
 
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S., Venetz J.P., Fontana M., Aubert J.D., Pascual M., Eap C.B., 2008. Therapeutic Drug Monitoring, 30 (6) pp. 689-699. Peer-reviewed.
 
Genotyping to optimize antipsychotic drug treatment
Eap Chin, 2008. p. 86 dans International Journal of Neuropsychopharmacology, International Journal of Neuropsychopharmacology. Peer-reviewed.
 
Impact of oral Cannabis on driving skills and genetic vulnerability to psychotic symptoms
Giroud C., Eap C.B., Favrat B., Sporkert F., Augsburger M., Rochat B., Montoya J.P., Castella V., Mangin P., 2008., Beiträge zum XV. Symposium der Gesellschaft für Toxigologische und Forensische Chemie. - Mosbach, 18-21. April 2007 pp. 193-203 dans Pragst F., Aderjan R. (eds.) Aktuelle Beiträge zur Forensischen und Klinischen Toxikologie. Fahreignung, K.O.-Mittel, Toxikokinetik, Analytische Methoden, Symposium der Gesellschaft für Toxicologische und Forensische Chemie : XV, Gesellschaft für Toxigologische und Forensische Chemie.
 
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients
Crettol Séverine, Venetz Jean-Pierre, Fontana Massimiliano, Aubert John-David, Ansermot Nicolas, Fathi Marc, Pascual Manuel, Eap Chin-Bin, 2008. Pharmacogenetics and Genomics, 18 (4) pp. 307-315. Peer-reviewed.
 
La génétique de l'hypertension: rôle des gènes CYP3A5 et ABCB1 dans le contrôle de la tension artérielle
Bochud Murielle, Eap Chin B., Bovet Pascal, Burnier Michel, 2008. Kardiovaskuläre Medizin, 11 (11) pp. 353-360.
 
Mico-cocktail validation for CYP3A and CYP2D6 assessment using a low dose of midazolam (0.075 mg) and dextromethorphan (2.5 mg)
Daali Y., Samer C., Eap C., Rebsamen M., Rossier M., Dayer P., Desmeules J., 2008. pp. 80S dans 76e Assemblée annuelle de la Société Suisse de Médecine Interne, Médecine et Société, Medizin und Gesellschaft, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
Monographs on drugs which are frequently analyzed in therapeutic drug monitoring = Arzneimittel-Monographien für Medikamente, die regelmässig im Rahmen des Therapeutic Drug Monitorings analysiert werden
Rentsch K., Eap C.B., Fathi M., Grignaschi N., Magnin J.L., Thormann W., Todesco L., Werner D., 2008. LaboratoriumsMedizin = Journal of Laboratory Medicine, 32 (5) pp. 372-381. Peer-reviewed.
 
No influence of ABCB1 haplotypes on methadone dosage requirement
Crettol Séverine, Déglon Jean-Jacques, Besson Jacques, Croquette-Krokar Marina, Hämmig Robert, Gothuey Isabelle, Monnat Martine, Eap Chin-Bin, 2008. Clinical Pharmacology and Therapeutics, 83 (5) pp. 668-669. Peer-reviewed.
 
Over- and underreporting of recent drug use in subjects entering an inpatient detoxification unit
Zullino Daniele Fabio, Krenz Sonia, Eap Chin-Bin, Benguettat Djamel, Khan R., 2008. European Journal of Medical Research, 13 (1) pp. 15-20. Peer-reviewed.
 
Pharmacogenetics of clozapine: in vivo role of cytochrome P450 isoforms and P-Glycoprotein
Jaquenoud Sirot Eveline, Knezevic B., Perla Morena Gina, Baumann Pierre, Eap Chin Bin, 2008. dans Pharmacopsychiatry, Pharmacopsychiatry. Peer-reviewed.
 
Response to "methadone-induced QTc prolongation: is it due to stereoselective block of hERG or to inappropriate QT interval correction?"
Crettol Séverine, Schlaepfer Jürg, Abriel Hugues, Eap Chin-Bin, 2008. Clinical Pharmacology and Therapeutics, 83 (5) p. 672. Peer-reviewed.
 
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizer: evidence of a safer cardiac profile of (R)-methadone
Eap Chin Bin, Crettol Séverine, Rougier Jean-Sébastien, Schläpfer Jürg, Sintra Grilo Liliana, Déglon Jean-Jacques, Besson Jacques, Croquette-Krokar Marina, Carrupt Pierre-Alain, Abriel Hugues, 2008. pp. A6 dans 5th Regensburg Symposium on Clinical Pharmacology, Pharmacopsychiatry. Peer-reviewed.
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1644-1668. Peer-reviewed.
 
Suivi thérapeutique des médicaments (II). La pratique clinique [Therapeutic drug monitoring: clinical practice].
Widmer N., Werner D., Grouzmann E., Eap C.B., Marchetti O., Fayet A., Csajka C., Decosterd L.A., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1649-1660. Peer-reviewed.
 
Clinical consequences of imatinib plasma concentrations variability in hemato-oncologic patients
Widmer N., Leyvraz S., Duchosal M.A., Rosselet A., Csajka C., Henry H., Debiec-Rychter M., Eap C.B., Biollaz J., Buclin T. et al., 2007. p. 481 dans 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
 
Clinical consequences of imatinib plasma concentrations variability in hemato-oncologic patients
Widemer Nicolas, Leyvraz Serge, Duchosal Michel A., Rosselet Anne, Csajka Chantal, Henry Hugues, Debiec-Rychter Maria, Eap Chin-Bin, Biollaz Jérôme, Buclin Thierry et al., 2007. p. 481 dans , Therapeutic Drug Monitoring. Peer-reviewed.
Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression?
Crettol S., Monnat M., Eap C.B., 2007. Critical Care, 11 (1) p. 119. Peer-reviewed.
 
CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt.
Eap C.B., Bochud M., Elston R.C., Bovet P., Maillard M.P., Nussberger J., Schild L., Shamlaye C., Burnier M., 2007. Hypertension, 49 (5) pp. 1007-14. Peer-reviewed.
 
Determination and distribution of clotiapine (Entumine) in human plasma, post-mortem blood and tissue samples from clotiapine-treated patients and from autopsy cases
Sporkert Frank, Augsburger Marc, Giroud Christian, Brossard Clarisse, Eap Chin-Bin, Mangin Patrice, 2007. Forensic Science International, 170 (2/3) pp. 193-199. Peer-reviewed.
 
Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label study
Le Bloc'h Yves, Baumann Pierre, Stigler Michael, Eap Chin-Bin, Zullino Daniele Fabio, 2007. International Journal of Psychiatry in Clinical Practice, 11 (2) pp. 123-128. Peer-reviewed.
 
In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites
Crettol Séverine, Digon Patricia, Powell Golay Kerry, Brawand Marlyse, Eap Chin-Bin, 2007. Pharmacology, 80 (4) pp. 304-311. Peer-reviewed.
 
Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients
Uehlinger Claude, Crettol Séverine, Chassot Philippe, Brocard Murielle, Koeb Liliane, Brawand-Amey Marlyse, Eap Chin-Bin, 2007. Journal of Clinical Psychopharmacology, 27 (3) pp. 273-278. Peer-reviewed.
 
Micro-cocktail validation for CYP3A and CYP2D6 assessment using a low dose of midazolam (0.075 mg) and dextromethorphan (2.5 mg)
Daali Youssef, Samer C., Eap Chin-Bin, Rebsamen Michaëla, Rossier Michel, Dayer Pierre, Desmeules Jules, 2007. pp. S77-S77 dans , Clinical Pharmacology and Therapeutics. Peer-reviewed.
 
Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements
Saraeva R. B., Paskaleva I. D., Doncheva E., Eap Chin-Bin, Ganev V. S., 2007. Journal of Clinical Pharmacy and Therapeutics, 32 (6) pp. 641-649. Peer-reviewed.
 
Pharmacokinetic and pharmacogenetic factors influencing methadone plasma levels
Crettol Séverine, Eap Chin-Bin, 2007. Heroin Addiction and Related Clinical Problems, 9 (2) pp. 39-46. Peer-reviewed.
 
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers.
Eap C.B., Crettol S., Rougier J.S., Schläpfer J., Sintra Grilo L., Déglon J.J., Besson J., Croquette-Krokar M., Carrupt P.A., Abriel H., 2007. Clinical Pharmacology and Therapeutics, 81 (5) pp. 719-728. Peer-reviewed.
 
The ABCB1 2677 G>T and 3435 C>T variants are associated with glomerular filtration rate in African families [Abstract]
Bochud Murielle, Eap Chin-Bin, Maillard Marc P., Elston Robert C., Bovet Pascal, Shamlaye Conrad, Burnier Michel, 2007. dans Biomedical imaging, CHUV Research Day, February 1, 2007. - Lausanne : CHUV, 2007. - MCV-32, p. 112, CHUV Research Day.
 
Time course of response to paroxetine: influence of plasma level
Gex-Fabry Marianne, Gervasoni Nicola, Eap Chin-Bin, Aubry Jean-Michel, Bondolfi Guido, Bertschy Gilles, 2007. Progress in Neuro-psychopharmacology & Biological Psychiatry, 31 (4) pp. 892-900. Peer-reviewed.
 
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S., Déglon J.J., Besson J., Croquette-Krokar M., Hämmig R., Gothuey I., Monnat M., Eap C.B., 2006. Clinical pharmacology and therapeutics, 80 (6) pp. 668-81. Peer-reviewed.
 
Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity
Stephan P.L., Jaquenoud Sirot E., Mueller B., Eap C.B., Baumann P., 2006. Pharmacopsychiatry, 39 (4) pp. 150-2. Peer-reviewed.
Apport de la pharmacogénétique dans le traitement médicamenteux des addictions : l'exemple de la méthadone
Eap C.B., Baumann P., 2006. pp. 65-70 dans Suchtforschung des BAG. Recherches de l'OFSP en matière de dépendances 2002-03, Bundesamt für Gesundheit.
 
Aripiprazole and suicidality.
Holzer L., Eap C.B., 2006. International clinical psychopharmacology, 21 (2) pp. 125-6. Peer-reviewed.
 
Association of CYP3A5 genotypes with blood pressure and renal function in African families.
Bochud M., Eap C.B., Elston R.C., Bovet P., Maillard M., Schild L., Shamlaye C., Burnier M., 2006. Journal of hypertension, 24 (5) pp. 923-9. Peer-reviewed.
 
Dose-dependent venlafaxine-induced hair loss
Jaquenoud Sirot Eveline, Etzensberger M., Eap Chin-Bin, Baumann Pierre, 2006. p. 939 dans , Drug Safety. Peer-reviewed.
 
Dépendances [Addictions]
Besson J., Eap C., Rougemont-Buecking A., Simon O., Nikolov C., Bonsack C., Gothuey I., 2006. Revue médicale suisse, 2 (47) pp. 9-13. Peer-reviewed.
 
Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status.
Baumann P., Barbe R., Vabre-Bogdalova A., Garran E., Crettol S., Eap C.B., 2006. Journal of clinical psychopharmacology, 26 (6) pp. 679-81. Peer-reviewed.
 
Genetic polymorphisms of CYP3A genes affect cyclosporine a blood concentration and dose requirement in transplant recipients
Crettol Séverine, Venetz Jean-Pierre, Aubert John-David, Fontana Massimiliano, Brocard Murielle, Pascual Manuel, Eap Chin-Bin, 2006. p. 197 dans NA, Transplantation. Peer-reviewed.
 
Influence of MDR1 genetic polymorphisms on intralymphocyte concentrations of cyclosporine A in transplant recipients
Crettol Séverine, Venetz Jean-Pierre, Aubert John-David, Fontana Massimiliano, Ansermot Nicolas, Fathi Marc, Brocard Murielle, Pascual Manuel, Eap Chin-Bin, 2006. p. 197 dans NA, Transplantation. Peer-reviewed.
 
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Colombo S., Buclin T., Décosterd L.A., Telenti A., Furrer H., Lee B.L., Biollaz J., Eap C.B. and , 2006. Clinical pharmacology and therapeutics, 80 (4) pp. 307-18. Peer-reviewed.
 
Pharmacogenomics of opioids
Crettol Séverine, Eap Chin-Bin, 2006. dans Pharmacogenomics and proteomics : enabling the practice of personalized medicine / ed. by Steven H.Y. Wong, Mark W. Linder, Roland Valdes. - Washington, DC : AAC Press, 2006. - P. 187-198. - ISBN 1594250464, NA.
 
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. British journal of clinical pharmacology, 62 (1) pp. 97-112. Peer-reviewed.
 
Prevalence of substance use in a Swiss psychiatric hospital: interview reports and urine screening.
Bonsack C., Camus D., Kaufmann N., Aubert A.C., Besson J., Baumann P., Borgeat F., Gillet M., Eap C.B., 2006. Addictive behaviors, 31 (7) pp. 1252-8. Peer-reviewed.
 
Relations entre la pharmacocinétique de population de l'imatinib et l'alpha-1-glycoproteine acide chez des patients hémato-oncologiques
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. dans 13es Journées Franco-Suisses de Pharmacie Hospitalière.
 
Relationship between imatinib population pharmacokinetics and alpha-1-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. pp. 71S dans 74e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
Holzer L., Eap C.B., 2006. Journal of clinical psychopharmacology, 26 (2) pp. 167-171. Peer-reviewed.
 
Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.
Jaquenoud Sirot E., van der Velden J.W., Rentsch K., Eap C.B., Baumann P., 2006. Drug safety, 29 (9) pp. 735-768. Peer-reviewed.
 
Association between the CYP3A5 A698G polymorphism and blood pressure in individuals of east African descent
Eap Chin-Bin, Bochud Murielle, Elston Robert C., Bovet Pascal, Maillard Marc P., Burnier Michel, 2005. pp. MCV-042, p. 145 dans , CHUV Research Day.
 
CYP2D6 genotype in relation to steady state concentrations of mirtazapine, N-desmethylmirtazapine and their enantiomers
Lind A.B., Reis M., Bengtsson Finn, Ahlner Johan, Eap Chin-Bin, Baumann Pierre, Dahl M.L., 2005. p. 124 dans , Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
 
Drug monitoring during substitution treatment
Eap Chin-Bin, 2005. pp. 15-16 dans European Psychiatry. Peer-reviewed.
 
Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients.
de Mendonça Lima C.A., Baumann P., Brawand-Amey M., Brogli C., Jacquet S., Cochard N., Powell-Golay K., Eap C.B., 2005. Progress in neuro-psychopharmacology & biological psychiatry, 29 (6) pp. 952-6. Peer-reviewed.
 
Follow-up of a pharmacovigilance study in psychiatry involving TDM and pharmacogenetic testing
Jaquenoud Sirot Eveline, Eap Chin-Bin, Baumann Pierre, 2005. pp. 54-55 dans , Pharmacopsychiatry. Peer-reviewed.
 
Genetic polymorphisms of psychotropic drug metabolizing enzymes: clinical relevance
Baumann Pierre, Jaquenoud Eveline, Eap Chin-Bin, 2005. p. 103 dans , European Psychiatry. Peer-reviewed.
 
High sedation with low doses of atypical antipsychotics in 3 young patients (13 to 14 years old)
Holzer Laurent, Eap Chin-Bin, Halfon Olivier, Baumann Pierre, 2005. p. 53 dans , Pharmacopsychiatry. Peer-reviewed.
 
Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients.
Bondolfi G., Morel F., Crettol S., Rachid F., Baumann P., Eap C.B., 2005. Therapeutic drug monitoring, 27 (4) pp. 539-43. Peer-reviewed.
 
Influence of CYP2B6 polymorphism on the steady-state plasma levels of the enantiomers of methadone
Crettol Séverine, Déglon Jean-Jacques, Besson Jacques, Croquette-Krokar Marina, Gottuey I., Haemming R., Monnat Martine, Haottemann H., Baumann Pierre, Eap Chin-Bin, 2005. p. 121 dans NA, Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
 
Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.
Nikisch G., Mathé A.A., Czernik A., Thiele J., Bohner J., Eap C.B., Agren H., Baumann P., 2005. Psychopharmacology, 181 (4) pp. 751-60. Peer-reviewed.
 
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S., Déglon J.J., Besson J., Croquette-Krokkar M., Gothuey I., Hämmig R., Monnat M., Hüttemann H., Baumann P., Eap C.B., 2005. Clinical pharmacology and therapeutics, 78 (6) pp. 593-604. Peer-reviewed.
 
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram.
Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., Mathé A.A., 2005. International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (cinp), 8 (3) pp. 403-410. Peer-reviewed.
 
Optimisation of psychopharmacotherapy: clinical relevance of pharmacogenetic tests and therapeutic drug monitoring
Baumann Pierre, Jaquenoud Sirot Eveline, Eap Chin-Bin, 2005. p. 229 dans , Pharmacopsychiatry. Peer-reviewed.
 
Pharmacokinetics and pharmacogenetics of methadone : clinical relevance
Eap Chin-Bin, Déglon Jean-Jacques, Baumann Pierre, 2005. dans Heroin-assisted treatment : work in progress / ed. by Margret Rihs-Middel...[et al.]. - Bern : H. Huber, 2005. - P. 251-265. - ISBN 3-456-83899-9.
 
Plasma-CSF concentrations relationship of psychotropic drugs
Baumann Pierre, Nikisch Georg, Eap Chin-Bin, 2005. p. 43 dans , Pharmacopsychiatry. Peer-reviewed.
 
Prevalence of methadone injection in three Swiss cities.
Chevalley A.E., Besson J., Croquette-Krokar M., Davidson C., Dubois J.A., Uehlinger C., Eap C.B., 2005. Presse Médicale, 34 (11) pp. 776-780. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University